Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
Angion’s Merger Agreement with Elicio Therapeutics
Angion Biomedica’s Initial Public Offering and Concurrent Private Placement
Latham & Watkins LLP represented Angion in the offering and private placement. Angion Biomedica Corp. (NASDAQ:ANGN) has announced the pricing of its initial public offering of 5...